11 results about "Daunorubicina" patented technology

The invention develops a double-line sequential targeted nano-drug delivery system, epigenetic regulation and traditional chemotherapy are combined, and the system is used for accurately and effectively treating acute myelogenous leukemia. The METTL3 inhibitor and the ROS-responsive daunorubicin prodrug are co-delivered in a single nano-drug, and the nano-preparation can realize continuous and double-path drug release according to the oxidation-reduction state in AML cells. In leukemia stem cells with low ROS level, STM2457 is released preferentially to induce differentiation and improve the ROS level of mitochondria, so that DA-ROS is activated, and the effect of delaying cytotoxicity is achieved. On the contrary, the AML mother cells with high ROS level can immediately trigger DA-ROS activation and release the two drugs at the same time, so that the tumor cells are directly killed. This ROS adaptive delivery strategy ensures spatial and temporal accuracy of drug release in heterogeneous AML cell populations.

The invention provides an anti-leukemia pharmaceutical composition based on DNA damage activated NKT cells and application of the anti-leukemia pharmaceutical composition. A mouse leukemia model is adopted as a research object, and experimental results show that in a C1498 homotransplantation tumor C57BL / 6 immune sound mouse leukemia model, the tumor inhibition rate of a daunorubicin and alpha-galactosylceramide combined treatment group reaches 67.4%, the survival time is remarkably prolonged, and obvious toxicity is not caused; in a C57 mouse leukemia model constructed by caudal vein injection of C1498, daunorubicin and alpha-galactosylceramide are combined to treat and reverse leukemia-related hepatosplenomegaly (the weight of liver and spleen is equivalent to that of a normal group), leukocyte proliferation is inhibited, and the survival state of mice is improved. The invention provides a new direction for treatment of leukemia.

The invention discloses a pharmaceutical composition containing a polysialic acid-melittin polyion compound and sialic acid modified anthracycline anti-tumor drug liposome and application of the pharmaceutical composition. The invention belongs to the technical field of biological medicine, and particularly relates to a targeted delivery pharmaceutical composition for treating cold tumors through immunotherapy, and the pharmaceutical composition comprises a polysialic acid-melittin polyion compound and sialic acid modified anthracycline antitumor drug liposome. The anthracycline antitumor drug is selected from one or more of the following components: doxorubicin, epirubicin, pirarubicin, idarubicin, daunorubicin or mitoxantrone. The pharmaceutical composition shows a remarkable synergistic effect in tumor inhibition index, can stimulate congenital immunity and adaptive immunity, induce multiple release of tumor-associated antigens and specific antigens, trigger tumor immune circulation and recover immune control of a body on tumors, and also can enable the body to generate immune memory, so that the tumor inhibition effect is improved. And a new combined treatment strategy is provided for cold tumor treatment.

This invention provides an Auger electron radiotherapy drug that can selectively and effectively release a sufficient amount of Auger electrons into the nuclear DNA of cancer cells, even in small amounts, thereby reducing or killing cancer cells. The Auger electron radioactive isotope has a half-life that is not too short but not too long, making it highly safe and readily available. [Solution] The Auger electron radioactive therapeutic agent is encapsulated in a stimulus-responsive liposome that accumulates in cancer tissue and / or cancer cells, such that an anthracycline derivative is released upon stimulation, in which an Auger electron-emitting radioisotope-substituted benzene ring-containing group or radioisotope-substituted alkyl group is covalently bonded to the keto or amino group of anthracyclines selected from doxorubicin or daunorubicin and their reduced forms or alkoxy group-substituted forms thereof, is a stimulus-responsive liposome, or is bound to an antibody, oligopeptide, or antigen that accumulates in cancer tissue and / or cancer cells via a stimulus-responsive linker.

The invention provides an exosome composition for reducing side effects of chemotherapy treatment and a preparation method of the exosome composition, and belongs to the technical field of medicines. The preparation method comprises the following steps: preparing a co-crystal from methotrexate, vinblastine and daunorubicin, loading the co-crystal on UiO-66-NH2 grafted with RGD, loading the co-crystal on exosome, embedding the UiO-66-NH2 and the exosome in a compound of acrylic acid, traditional Chinese medicine polysaccharide and pullulan to prepare a slow-release long-half-life exosome system, and uniformly mixing the slow-release long-half-life exosome system with D-ribose, yeast-beta glucan and glutathione to prepare a sustained-release long-half-life exosome. The traditional Chinese medicine polysaccharide is obtained by carrying out boiling water extraction and ethanol precipitation on codonopsis pilosula, angelica sinensis, polygonatum kingianum and dendrobium officinale kimura et migo. The exosome composition for reducing the side effects of chemotherapy is prepared, the drug resistance of tumor cells is reduced, the drug effect is improved, the side effects after chemotherapy are reduced, the effect of targeted slow release of drugs is achieved, and the exosome composition has wide application prospects.

The invention discloses application of brutinib and a combined pharmaceutical composition thereof in treatment of leukemia, and the leukemia comprises acute myelogenous leukemia, chronic myelogenous leukemia, T acute lymphoblastic leukemia and B acute lymphoblastic leukemia. The invention creatively finds that the brutinib has a remarkable synergistic effect on treatment of the leukemia when being combined with the vinca, the cytarabine or the daunorubicin for use, and a brand new drug combination scheme provided by the invention provides a more effective drug combination choice for treatment of the leukemia, and is expected to improve the treatment effect of patients with the leukemia.

(3R, 4S)-3-(4-hydroxy-3,5-dimethoxyphenyl)-4-(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H- chromen-7-ol (TRX-E-002-1) for use in a method of treatment for a hematological cancer being acute myeloid leukemia or multiple myeloma in a subject in need thereof, the method comprising administering to the subject an effective amount of TRX-E-002-1. The method may further comprise administering to the subject an effective amount of a second compound selected from the group consisting of (i) a BCL-2 inhibitor such as venetoclax, navitoclax or obatoclax, (ii) a deoxycytidine analogue chemotherapeutic such as cytarabine or gemcitabine, (iii) a hypomethylating agent such as azacitidine or decitabine, (iv) an anthracycline chemotherapeutic such as daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin or mitoxantrone, (v) a proteasome inhibitor such as carfilzomib, bortezomib, and ixazomib, (vi) an immunomodulatory drug such as pomalidomide, lenalidomide, and thalidomide and(vii) a corticosteroid drug such as dexamethasone or prednisone, and (viii) an alkylator such as bendamustine, cyclophosphamide, melphalan, and melflufen. Corresponding combination pharmaceutical compositions.

The invention provides a method for improving the efficiency of preparing daunorubicin by fermenting streptomyces coeruleorubidus, which is used for improving the expression quantity of dnrK gene in streptomyces coeruleorubidus. The invention also provides a streptomyces coeruleorubidus genetic engineering strain, which is obtained by replacing an endogenous promoter at the upstream of a methyltransferase / decarboxylase coding gene dnrK with a promoter with a sequence of SEQ ID NO: 3. According to the invention, the strong promoter is utilized to over-express the methyltransferase / decarboxylase coding gene dnrK, the streptomyces coeruleorubidus strain is modified, the yield of daunorubicin of the dnrK over-expressed engineering bacteria is increased by 46%, and technical support is provided for increasing the yield of daunorubicin in industrial production.

The invention relates to compositions and methods for treating patients with hematological proliferative disorders with CPX-351, a liposomal composition of daunorubicin and cytarabine, and venetoclax.

The application provides an exosome composition for reducing side effects of chemotherapy treatment and a preparation method thereof, and belongs to the technical field of medicines. Methotrexate, vinblastine and daunorubicin are prepared into a co-crystal, loaded on UiO-66-NH2 connected with RGD, loaded on exosomes, and embedded in an acrylic acid, traditional Chinese medicine polysaccharide and pullulan compound to obtain a sustained-release high half-life exosome system, which is uniformly mixed with D-ribose, yeast-beta glucan and glutathione to obtain the exosome composition for reducing side effects of chemotherapy treatment. The traditional Chinese medicine polysaccharide is traditional Chinese medicine polysaccharide obtained by boiling water extraction and ethanol precipitation of radix codonopsis, angelica, polygonatum sibiricum and dendrobium officinale. The exosome composition for reducing side effects of chemotherapy treatment is prepared, drug resistance of tumor cells is reduced, drug efficacy is improved, side reactions after chemotherapy are reduced, the effect of targeted slow release of drugs is achieved, and the exosome composition has a wide application prospect.

The present invention relates to a novel prodrug of the disulfide of aldonolactone reductase inhibitor II based on its formula I (systematic name "disulfalane"), to a method of preparing the disulfide of formula I, to the use of the disulfide of formula I for inhibiting the aldonolactone reductases AKR1B1 and AKR1B10, to the use of the disulfide of formula I in the prevention or treatment of diseases in which the activity of the aldonolactone reductases AKR1B1 and AKR1B10 is a key cause of the formation and development of said diseases, to the use of the disulfide of formula I for the prevention or treatment of cancers derived from chronic inflammation, i.e. colon cancer, lung cancer, breast cancer, liver cancer, prostate cancer, pancreatic cancer, endometrial cancer and cervical cancer. The present invention also relates to the use of the disulfide of formula I as an adjuvant therapy drug in combination with clinically used chemotherapeutic drugs, which can also be substrates of aldonolactone reductases, such as doxorubicin and daunorubicin, for the treatment of cancer. The disulfide of formula I is not active as an inhibitor of the aldonolactone reductases AKR1B1 and AKR1B10 itself, but after oral or parenteral administration it is metabolized in the body, preferably in cancer cells characterized by an increased reducing potential due to a significantly increased GSH content compared to healthy cells, thus producing two molecules of semimestar of formula II, i.e. an inhibitor of the activity of aldonolactone reductases. The disulfide of formula I according to the present invention can also have the advantage that it is better absorbed in the acidic environment of the tumor compared to semimestar of formula II alone. The disulfide of formula I can be used alone or in a pharmaceutically acceptable form: mono- or di-salt, mono- or di-ester, amide or combinations thereof or other agents, optionally in combination with other anti-inflammatory or anticancer therapeutic drugs.(I)